Riskpilot← Back to searchSign inGet full accessEnteroTarget ApS
APSActiveCVR 39315769Fruebjergvej 3Manufacture of pharmaceutical preparations · NACE 2120Est. 20181 employeesenterotarget.com
Revenue 2024
DKK -535K
-634% vs 2023
EBITDA margin
102.1%
-857% vs 2023
Equity ratio
13.0%
Financial strength
Net profit 2024
DKK -258K
-191% vs 2023
| Revenue | DKK -535K | -634% |
| EBITDA | DKK -546K | -857% |
| Net profit | DKK -258K | -191% |
| Total assets | DKK 3,7M | +142% |
| Equity | DKK 484K | -35% |
| Employees | 1 | — |
Legal name
EnteroTarget ApS
CVR number
39315769
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
2. februar 2018
Share capital
DKK 55.548
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af én direktør i forening med ét medlem af bestyrelsen eller af den
samlede bestyrelse.
Company purpose
Selskabets formål er at udvikle lægemidler til behandling af sygdomme i mavetarmkanalen
hos mennesker og dyr og hermed efter ledelsens skøn beslægtet virksomhed.
Address
Fruebjergvej 3
Phone
+4520770637
Email
jo@enterotarget.com
Website
enterotarget.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | -39 | -20 | 60 | -338 | 36 | 100 | -535 |
| Staff expenses | -0 | -0 | -0 | -0 | -10 | -28 | -11 |
| EBITDA | -39 | -20 | 60 | -338 | 26 | 72 | -546 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -39 | -20 | 60 | -338 | 26 | 72 | -546 |
| Net financials | 0 | 0 | -0 | -6 | -32 | -29 | -209 |
| Profit before tax | -39 | -20 | 60 | -344 | -7 | 43 | -756 |
| Tax | -9 | -4 | 13 | -76 | -0 | -239 | -498 |
| Net profit | -31 | -15 | 47 | -268 | -7 | 282 | -258 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 26 | 211 | 362 | 297 | 974 | 1.540 | 3.725 |
| Equity | 20 | 205 | 252 | -17 | 460 | 742 | 484 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 6 | 6 | 110 | 314 | 514 | 798 | 3.241 |
| Total debt | 6 | 6 | 110 | 314 | 514 | 798 | 3.241 |
EBITDA margin
-54631300.0%
This company
15.8%
Market median
-345767822% vs market
20182024
Equity ratio
13.0%
This company
38.2%
Market median
-66% vs market
20182024
Return on equity
-53.2%
This company
18.4%
Market median
-389% vs market
20182024
Net profit margin
-25794200.0%
This company
8.1%
Market median
-318447014% vs market
20182024
Asset turnover
-0.14×
This company
1.12×
Market median
-113% vs market
20182024
Debt / equity
6.69×
This company
0.62×
Market median
-979% vs market
20182024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-02-02 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JO Management | Management | 2018 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
NEO Anderson Holding ApS | Company | 33.3% | 33.3% | 2018 |
| Individual | 15.0% | 15.0% | 2022 | |
Yassin Holding ApS | Company | 15.0% | 15.0% | 2025 |
TroePaz Holding ApS | Company | 15.0% | 15.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Jolsen Holding ApS
EnteroTarget ApS Board members of EnteroTarget ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jørgen Olsen | Management | 0 companies |
| Sebastien Olivier Marie Pratt | Board of Directors | 0 companies |
| Jesper Thorvald Troelsen | Chairman | 0 companies |
| Mohammad Taha Yassin | Board of Directors | 0 companies |
| Charlotte Dyring | Board of Directors | 0 companies |
| Benny Buchardt Andersen | Board of Directors | 0 companies |
| Aditi Singh Ulvskjold | Board of Directors | 0 companies |